"New COVID-19 Vaccine Shows Strong Protection Against Latest Variant, CDC Reports"

Early estimates from the CDC's Advisory Committee on Immunization Practices show that the updated 2023–2024 monovalent XBB.1.5 COVID-19 vaccine provides approximately 54% increased protection against symptomatic SARS-CoV-2 infection compared to no receipt of the updated vaccine. The vaccine offers protection against the JN.1 and other co-circulating lineages, and it is recommended that all persons aged ≥6 months should receive the updated COVID-19 vaccine. The CDC will continue monitoring vaccine effectiveness, including against severe disease and for expected waning.